The obtained results demonstrated that ATF4 silencing contributed to protection against AP via inhibiting the recruitment of HDAC1 in the NEP promoter and downregulating KLF4, providing a novel insight into developing potential therapeutic strategy for AP. The gene discussed is ATF4; the disease is alkaline phosphatase measurement.